Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Psoriasis is a chronic, recurrent, and incurable autoimmune disease in which the body mistakenly attacks its own tissue, ...

Arrowhead Pharmaceuticals disclosed that its gene-silencing candidates helped people with obesity lose fat, very early ...

Psoriasis severity and quality of life appeared to improve with weight-loss interventions in a systematic review.

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced a new presentation of Otulfi® ...

Alumis Inc. ( ($ALMS) ) just unveiled an announcement. On January 6, 2026, Alumis reported positive topline Phase 3 results from its ONWARD1 and ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed ...